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Purpose: The aim of the present study was to develop and optimize sinomenine hydrochloride (SIN) in situ
gel for uveitis treatment.
Methods: Carbopol 940 was used as the gelling agent in combination with hydroxypropyl methylcellulose
(HPMC), which acts as a viscosity enhancer. The formulations were prepared using various concentrations
of Carbopol 940 and HPMC. The prepared in situ gels were evaluated for gellation, drug release, ocular irrita-
tion, elimination time and pharmacokinetic studies. Furthermore, the effect of SIN on the development of ex-
perimental autoimmune anterior uveitis (EAAU) was assessed.
Results: The optimum concentration of Carbopol was 0.1% (w/v), and that for HPMC was 0.4% (w/v). Which
showed a signiﬁcant enhancement in gel strength in the physiological condition while free ﬂowing at
non-physiological condition. Optimum formula F2–3 consisting of 0.5% SIN was prepared and kept as gel
group, and 0.5% SIN solution was prepared and kept as control group. Gel group provided sustained release
of the drug over a period of 480 min. No evidence of overt toxicity and irritation was observed in any
study. The elimination time of control group and gel group was completed within 10 min and 25 min, re-
spectively. The area under the aqueous humor concentration vs. time curve (AUC0–t) and maximum concen-
tration (Cmax) values of gel group was 2.70-fold and 1.79-fold higher than that of control group. Additionally,
clinical examination showed that SIN suppressed inﬂammation in EAAU.
Conclusions: These results support the potential applications of SIN in situ gel for uveitis treatment.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Uveitis is an inﬂammatory eye disease characterized by intraocular
inﬁltration of various populations of leukocytes, and is a Th-1 mediated
autoimmune disease [1,2]. Uveitis, a common cause of vision loss, ac-
counts for 5% to 15% of all cases of blindness worldwide affecting indi-
viduals of all ages, both sexes, and all races [3]. Possible complications
of chronic uveitis include glaucoma, cataracts, accumulation of ﬂuids
within the retina, retinal detachment and vision loss [4,5]. Therefore,
control of inﬂammation in uveitis is critical to minimize the vision
loss. For the treatment of uveitis, non-steroidal anti-inﬂammatory
drugs (NSAIDs), steroidal agents and immunosuppressants are usually
used. However, these drugs are known to produce various side effects,t, the Afﬁliated Eye Hospital of
8#, Yingxiongshan Road, Jinan
1 82861167.
B.V. Open access under CC BY-NC-ND lsuch as increased intraocular pressure, cataract and immunodeﬁciency
[6–8]. Efforts need to be made to seek therapeutic agents that can be
used for long-term administration. EAAU in rats is an animal model of
organ-speciﬁc autoimmune inﬂammatory disease of the eye that
bears close resemblance to human idiopathic anterior uveitis [9]. Vari-
ous investigators have suggested the use of these animal models to
study the efﬁcacy of pharmacologic inhibitors in patients [10,11].
For many decades, numerous bioactive products isolated from vari-
ous natural resources have inﬂuenced modern drug discovery across
the therapeutic spectrum. Therefore, great efforts have been made to
discover lead compound from natural product in an attempt to obtain
new anti-inﬂammatory drugs. The alkaloid sinomenine is a pure com-
pound extracted from the Chinesemedicinal plant, Sinomeniumacutum,
which has been utilized to treat inﬂammatory diseases for many centu-
ries. A vast number of pharmacological and clinical studies performed in
China and Japan have demonstrated that the pure alkaloid extract pos-
sesses anti-inﬂammatory and immunoregulatory properties, as well as
mild sedative and analgesic actions due to its chemical structure,
which is similar to morphine [12–15]. Chemically, sinomenine hydro-
chloride is 7, 8-didehy-dro-4-hydroxy-3, 7-dimethoxy-17-methyl-(9a,
13a, 14a)-morphinan-6-one (Fig. 1), which has a molecular weight oficense.
Fig. 1. The molecule structure of SIN.
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has been proven beyond doubt in the treatment of systemic dis-
eases such as rheumatoid arthritis (RA), juvenile idiopathic arthri-
tis (JIA), as well as endogenous, non-infectious refractory uveitis
and other immune-related diseases [16–19]. Based on its potent
anti-inﬂammatory properties, sinomenine was also taken into con-
sideration for the treatment of allogeneic graft rejection and was
found to effectively inhibit allograft rejection [20]. However, like
other NSAIDs, SIN may cause gastric intestine and kidney damage,
and besides may affect liver and heart after long-term treatment
[21,22], which makes the topical dosage forms of SIN an attractive
alternative delivery route to avoid the oral side effects and provide
relatively consistent drug levels for prolonged periods.
The conventional eye drops are eliminated from the precorneal area
immediately and only 1–10% of topically applied drug is absorbed [23],
which also includes absorption into the gastrointestinal tract due to
drainage through the nasal lacrimal duct [24]. The short precorneal con-
tact time combinedwith corneal impermeability results in lowbioavail-
ability, and as a result, frequent instillation of concentrated solutions is
needed in order to achieve the desired therapeutic effects [25,26]. In
order to increase the effectiveness of the drug a dosage form should
be chosen which increases the contact time of the drug in the eye.
This may increase the bioavailability, reduce systemic absorption and
reduce the need for frequent administration leading to improved pa-
tient compliance [27].
Various ophthalmic vehicles such as inserts, ointments, aqueous
gels and nanosuspension, have been developed in order to lengthen
the residence time of instilled dose and enhance the ophthalmic bio-
availability [28,29]. These ocular drug delivery systems, however,
have not been used extensively because of some drawbacks such as
blurred vision from ointments or low patient compliance from in-
serts [30]. Several in situ gel forming system have been developed
to prolong the pre-corneal residence time of a drug and improve oc-
ular bioavailability. Gels of pharmaceutical signiﬁcance have been
prepared by using various types of materials. Carbopol is a
polyacrylicacid (PAA) polymer, which shows a sol to gel transition
in aqueous solution as the pH is raised above its pKa of about 5.5
[31]. Carbopols are essentially nontoxic and nonirritant materials
with no evidence of their hypersensitivity in human subjects when
used topically [32]. However, the concentration of carbopol required
to form stiff gel results in highly acidic solutions, which are not easily
neutralized by the buffering action of the tear ﬂuid [33]. A reduction
in carbopol (anionic polymer) concentration without compromising
the gelling capacity and rheological properties of the delivery system
was achieved by the addition of viscosity enhancing polymers such
as HPMC.
The objective of the present research was to develop a pH-triggered
in situ gelling system for sustained ophthalmic delivery of SIN. A combi-
nation of Carbopol 940 and HPMC was investigated as vehicle for theformulation of eye drops of SIN (0.5%, w/v) that would gel when
instilled into the eye, and provide sustained release of SIN during treat-
ment of uveitis and some other ocular inﬂammation.
2. Materials and methods
2.1. Materials
2.1.1. Chemicals
Carbopol (940PNF, B. F. Goodrich),HPMC(Methocel K4M)were kind-
ly gifted by Colorcon (UK). SIN (>98%) and ﬂuorescein disodium salt
were obtained fromShaanxi Sciphar Biotechnology Co., Ltd (China). Pred-
nisolone acetate eye drops was purchased from YanLiJian Pharmaceutical
Co., LTD (Hangzhou, China). Inter-photoreceptor retinoid-binding protein
(IRBP) was purchased from Shanghai Sangon Biological Engineering
Technology & Services Co., Ltd (China). Freund's complete adjuvant was
purchased from Sigma-Aldrich, St. Louis, MO. All other chemicals and sol-
vents were of analytical grade.
2.1.2. Animals
Female Lewis rats (160–180 g) of speciﬁc pathogen-free grade were
purchased from Peking Vital River Laboratory Animal Technology Co.,
Ltd., Beijing, China. White New Zealand rabbits weighing 2.0–3.0 kg
and free of any signs of ocular inﬂammation or gross abnormalities
were obtained from the Animal Experimental Center of the Shan-Dong
University. All animals were fed andmaintained according to the guide-
lines of Care and Use of Laboratory Animals published by the China
National Institute of Health. All experimental procedures adhered to
the Association for Research in Vision and Ophthalmology Statement
for the use of animals in ophthalmic and vision research.
2.2. Liquid chromatography
SIN content in the samples was quantitated by reversed phase
(RP)-HPLC (Agilent 1100, HP Inc., USA; Diamonsil® C18 column,
250 mm × 4.6 mm, 5 μm, Dikma Technology Co., China). The column
temperature was maintained at 30 °C. The mobile phase consisted
of acetonitrile:water:triethylamine (21:79:0.05, v/v) at a ﬂow of
1 ml min−1. Detection was performed at 262 nm. A 20 μl aliquot of
the sample solution was loaded onto the column.
2.3. Preparation of pH-triggered gels
2.3.1. Selection of polymer composite
Aqueous solutions of varying concentrations of Carbopol 940 and
HPMC (formulation codes F1–1, F1–2,…, F3–5) were prepared and evalu-
ated for gelling capacity and viscosity in order to identify the composi-
tions suitable for use as in situ gelling systems (Table 1). The gelling
capacity was determined by placing 100 μl of the system in a vial
containing 2 ml of artiﬁcial tearﬂuid (NaCl 0.670 g, sodiumbicarbonate
0.200 g, calcium chloride·2 H2O 0.008 g, puriﬁed water q.s. 100.0 g)
freshly prepared and equilibrated at 37 °C and visually assessing gel for-
mation and noting the time for gelation and the time taken for the gel
formed to dissolve. Viscosity at 20 rpm was measured using a Brook-
ﬁeld Synchrolectric viscometer (RVT model) in a small volume adapter
used for purposes of comparative evaluation. The pH of all the sample
solutions was adjusted by 0.1 M triethanolamine solution.
2.3.2. Preparation of pH induced in situ gel
A concentrated Carbopol 940 solutionwas obtained andHPMCwas
added and allowed to hydrate. For preparations of SIN-containing
polymer solutions, the desired amounts of SIN were added to the
Carbopol/HPMC solutions with continuous stirring until thoroughly
mixed. Benzalkonium chloride (BKC) was then added and the solu-
tions were ﬁltered through 0.2 mm cellulose acetate membrane ﬁlter.
The solutions were then brought to volume 100 ml with puriﬁed
Table 1
Combination of Carbopol 940 and HPMC (K4M) studied (mean ± SD, n = 3).
Formulations Contents (%, w/v) Gelling capacity Viscocity (mPa s at 20 rpm)
Carbopol 940 HPMC (K4M) pH 5.5 ± 0.2 pH 6.0 ± 0.2 pH 7.0 ± 0.2
F1–1 0.08 0.1 − 100 ± 5 325 ± 7 500 ± 19
F1–2 0.08 0.2 + 140 ± 7 560 ± 14 700 ± 21
F1–3 0.08 0.4 + 255 ± 11 840 ± 15 1000 ± 23
F1–4 0.08 0.6 +++ 680 ± 13 1400 ± 31 2800 ± 140
F1–5 0.08 0.8 +++ 900 ± 87 3700 ± 107 5400 ± 130
F2–1 0.1 0.1 + 285 ± 23 740 ± 54 1360 ± 98
F2–2 0.1 0.2 + 305 ± 12 980 ± 43 1800 ± 120
F2–3 0.1 0.4 ++ 700 ± 85 1120 ± 49 4300 ± 120
F2–4 0.1 0.6 +++ 840 ± 22 5900 ± 250 7400 ± 310
F2–5 0.1 0.8 +++ 1360 ± 145 7100 ± 440 7600 ± 360
F3–1 0.12 0.1 + 305 ± 32 900 ± 55 1100 ± 110
F3–2 0.12 0.2 ++ 860 ± 105 1580 ± 40 4200 ± 100
F3–3 0.12 0.4 +++ 1500 ± 150 3500 ± 97 4400 ± 110
F3–4 0.12 0.6 +++ 2400 ± 240 4200 ± 120 5500 ± 220
F3–5 0.12 0.8 +++ 2900 ± 250 7800 ± 350 7600 ± 340
Note: −, no gelation; +, gels after a few minutes, dissolves rapidly; ++, gelation immediate, remains for few hours; +++, gelation immediate, remains for extended period.
Fig. 2. In vitro release study: cumulative amount of SIN released as a function of time from
various formulations (mean ± SD, n = 4). Formula F2–3 consisting of 0.5% SIN was pre-
pared and kept as the gel group, and 0.5% SIN solution was prepared and kept as the con-
trol group.
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to equilibrate for 24 h at room temperature prior to the evaluation both in
vitro and in vivo.
2.4. In vitro release studies
According to previous reports [23], the in vitro release test was done
using a membrane less dissolution model (4.0 cm i.d. and 0.9 cm in
depth) with a dissolution testing apparatus (ZRS-8G, Tianjin, China). A
1 ml volume of the formulationwas accurately pipetted into this equip-
ment. The container was immersed in 500 ml freshly prepared STF,
which was used as the release medium. The temperature and rotating
rate were maintained at 34 ± 1 °C and 50 rpm, respectively. Aliquots
(5 ml) were withdrawn from the release mediums at each sampling
time and replaced by an equal volume of the release medium. The sam-
ples were ﬁltered through 0.45 μm syringe ﬁlters, and were subjected
to HPLC analysis to determine the SIN concentrations.
2.5. Ocular irritation studies
In this study, both the Draize method and histological examina-
tion were used to evaluate the ocular irritation of 0.5% SIN solution
and 0.5% SIN in situ gel.
2.5.1. Evaluation with the Draize method
Ocular irritationwas evaluated according to the Draizemethod [34].
Rabbits were treated with different ophthalmic formulations (control
group or gel group). Draize method ocular irritation scores for every
rabbit were calculated by adding the irritation scores for the cornea,
iris, and conjunctiva. The eye irritation score was obtained by dividing
the total score for all rabbits by the number of rabbits. Irritation was
classiﬁed according to four grades: non-irritating, score 0–3; slightly ir-
ritating, score 4–8; moderately irritating, score 9–12; and severely irri-
tating, score 13–16.
2.5.2. Histological examination
The effects of SIN on corneal structure and integrity were examined
in vitro. Corneas were removed from the eyes of freshly sacriﬁced rab-
bits and incubated at 37 °C for 2 h in 0.5% SIN solution (control
group) or 0.5% SIN in situ gel (gel group). Sodium dodecylsulfate
(SDS) solution in phosphate buffer saline (PBS) 0.1% (w/w) was used
as the positive control. After incubation, corneas were washed with
PBS and immediately ﬁxed in formalin (8%, w/w). Tissues were
dehydrated in an alcohol gradient, placed in melted parafﬁn, and solid-
iﬁed in block form. Cross sections (b1 μm) were cut, stained withhaematoxylin and eosin (H&E), and microscopically observed for any
pathological modiﬁcations.
2.6. In vivo elimination study
To reach the goal of studying the elimination time of the gels we dis-
persed ﬂuorescein disodium salt in the preparations since they were
well retained in the gel and easily visualized using a slit lamp. 50 μl of
each preparation was added into the lower conjunctival sac of rabbit
(n = 3), a slit lamp with blue light was used to monitor the disappear-
ance of the ﬂuorescein disodium salt. At selected time intervals the eyes
were inspected, when only a minute amount or none of the gel
remained it was considered as lost from the eye. The foregoing time
for inspection was deﬁned as the elimination time.
2.7. Ocular pharmacokinetics
In this study, rabbits (n = 3) had been treated with 0.3% (w/v)
oﬂoxacin ophthalmic solution for 4-day before surgery. Pupils were
dilated by topical instillation of 0.4% tropicamide prior to the probe
implantation. Before the probe implantation, the rabbits were anes-
thetized with sodium pentobarbital injected through the marginal
Table 2
Ocular irritation test results for multiple ophthalmic drug formulations (n = 3).
Formulations Parameters Ocular irritation scores
1 h 2 h 4 h 24 h 48 h 72 h
Control group Corneal Opacity 0 0 0 0 0
Iris 0 0 0 0 0 0
Conjunctivae 7 6 3 0 0 0
Average Score 1.75 1.5 0.75 0 0
Gel group Corneal Opacity 0 0 0 0 0
Iris 0 0 0 0 0 0
Conjunctivae 6 5 3 0 0 0
Average Score 1.5 1.25 0.75 0 0
Note: Formula F2–3 consisting of 0.5% SIN was prepared and kept as the gel group, and
0.5% SIN solution was prepared and kept as the control group.
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experiment. A custom designed CMA 30 linear microdialysis probe
(CMA/AB Microdialysis, Sweden) was implanted into the anterior
chamber of each eye as described previously [35]. After probe im-
plantation, the animals were allowed to stabilize for 2 h. And then
probes were perfused with IPBS at a ﬂow rate of 2 μl min−1 using
the CMA 402 syriage pump (CMA/AB Microdialysis, Sweden).
To determine in vivo probe calibration, the microdialysis probe
was perfused at a rate of 2 μl min−1 with different concentrations
of standard SIN IPBS solution. Dialysates were collected for 20 min
after 30 min of perfusion. The dialysate (20 μl) was injected into
the HPLC column and drug levels were determined. Relative recov-
ery is expressed as a ratio of drug concentration in dialysate to that
in the solution bathing the dialysis membrane. Recovery (R) is the
ratio of drug concentration in the dialysate (Cd) to that in the aque-
ous humor (Ca), calculated according to the following equation:
Rin vivo ¼
Cd−Cp
Ca−Cp
where Cp is the SIN concentration in the perfusate. Cd is the concen-
tration of dialysate and Ca is the concentration in aqueous humor. A
linear equation was plotted by (Cd − Cp) vs. Cp, and the slope of the
line gave the recovery (Rin vivo).
The probe was perfused with IPBS at a ﬂow rate of 2 μl min−1. After
that, an aliquot (100 μl) of control group or gel group formulation was
instilled in the lower cul-de-sac of each eye, and the upper and lower
eyelids were gently held closed for 10 s to maximize drug cornea con-
tact. The experiment was continued for 8 h after instillation of the for-
mulation. Samples were collected every 20 min within 2 h or every
30 min during the 3rd hour after instillation. At the end of the experi-
ment, euthanasia was performed under deep anesthesia with an intra-
venous injection of sodium pentobarbital through the marginal ear
vein. Samples were analyzed by HPLC.
Drug concentration in aqueous humor was calculated from relative
recovery in vivo and drug levels in dialysates. The values of the PKFig. 3. Ocular irritation was evaluated by both the Draize method and histological examinatio
different formulations. The ocular condition was recorded and photographed at 1, 2, 4, 24, 4
ment; (II) Rabbit eyes were treated with 0.5% SIN eyedrops. (III) Rabbit eyes were treated w
cised rabbit cornea demonstrating epithelium (EP) and stroma (ST) stained with hematoxy
dodecylsulfate (SDS) solution 0.1% (w/w) (positive control); (II) corneas were incubated w
in situ gel (gel group). Scale bar = 100 μm.parameters were calculated with noncompartmental analysis by the
software program DAS (version 2.0, Chinese Pharmacological Associa-
tion), including the maximum concentration (Cmax), time to reach the
maximum concentration (Tmax), area under concentration–time curve
(AUC0–t), half-life of elimination (t1/2), andmean residence time (MRT).
2.8. Induction and assessment of EAAU
2.8.1. Induction of EAAU
Thepeptidewas prepared by emulsiﬁcation of 100 μg IRBP1177–1191
peptide in Freund's complete adjuvant containing 2.5 mg ml−1 of myco-
bacterium tuberculosis H37Ra in a total volume of 0.1 ml. Female Lewis
rats were immunized by an injection of 0.1 ml peptide antigen in each
footpad.
2.8.2. Clinical examination and assessment
The immunized rats were divided into four groups (blank group,
control group, gel group and positive control group) with 5 in each
group. Theywere intervened 3 times per day from theﬁrst day after im-
munization. And 5 unimmunized rats were set as normal control group.
Normal control group was treated without any drops. Blank group wasn. (A): Draize method: Rabbits were treated once every 30 min for 6 h (12 times) with
8, and 72 h after the last administration. (I) Rabbit eyes were dealt without any treat-
ith 0.5% SIN in situ gel. (B): Histological examination: Histological cross sections of ex-
lin–eosin after incubation at 37 °C for 0.5 h. (I) Corneas were incubated with sodium
ith 0.5% SIN solution (control group); and (III) corneas were incubated with 0.5% SIN
Fig. 5. In vivo transcorneal absorption of SIN after ophthalmic administration of 0.5% SIN
solution (control group) or 0.5% SIN in situ gel (gel group). Values represent mean ±
SD. (n = 3).
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Gel group was treated with 0.5% SIN in situ gel. Positive control group
was treated with 1% prednisolone acetate eye drops. The rats were clin-
ically observed on a daily basis with slitlamp biomicroscopy for clinical
signs of ocular inﬂammation and scored according to acknowledged
criteria [36]. Severity of EAAU was scored on a scale of 0 (no disease)
to 4 (maximum disease). Disease severity was clinically assessed with
a scale ranging from 0 to 4: 0 = normal; 1 = slight iris-vessel dilata-
tion and some anterior chamber cells; 2 = Iris hyperemia, with some
limitation in pupil dilation, anterior chamber cells, and a slight ﬂare;
3 = amiotic, irregular, hyperaemic, and (sometimes) slightly damaged
iris, with a considerable ﬂare and cells (especially with accumulation
near the iris); and 4 = a seriously damaged and hyperaemic iris, a mi-
otic pupil often ﬁlled with protein, and cloudy gellike aqueous humor.
2.8.3. Eye histopathology
The immunized rats were divided into two groups (blank group, gel
group) with 3 in each group. And 3 unimmunized rats were set as nor-
mal control group. They were intervened 3 times per day from the ﬁrst
day after immunization. Normal control groupwas treated without any
drops. Blank group was treated with PBS. Gel group was treated with
0.5% SIN in situ gel. Rats were sacriﬁced at day 14 post-immunization
(peak of EAAU) and the eyes were enucleated. Freshly enucleated rat
eyes were ﬁxed in neutral buffered 10% formalin solution for 24 h at
room temperature, dehydrated in ethanol and embedded in parafﬁn.Fig. 4. In vivo elimination study. Fluorescein disodium salt was dispersed in the preparation
conjunctival sac of rabbit, a slit lamp with blue light was used to monitor and photograph
group was dropped. (I–VI: 0, 5, 10, 15, 20, 25 min). (B) Elimination time after the control gro
and kept as the gel group, and 0.5% SIN solution was prepared and kept as the control grouThen, 5 μm sagittal sections were cured and stained with hematoxylin
and eosin (H&E) for histopathologic analysis. Sections were examined
using a light microscope (Nikon Eclipse 55i, Japan).s and visualized using a slit lamp. 50 μl of each preparation was added into the lower
the disappearance of the ﬂuorescein disodium salt. (A) Elimination time after the gel
up was dropped. (I–III: 0, 5, 10 min). Formula F2–3 consisting of 0.5% SIN was prepared
p.
Table 3
Pharmacokinetic parameters of SIN in aqueous humor (mean ± SD, n = 3).
Parameters Control group Gel group
AUC(0–8) (μg ml–1 h) 13.46 ± 2.32 36.27 ± 3.54⁎
Cmax (μg ml–1) 0.15 ± 0.02 0.27 ± 0.02⁎
Tmax (min) 40 40
t1/2 (min) 65.94 ± 4.32 81.64 ± 6.61⁎
MRT(0–8) (h) 100.89 ± 8.33 124.16 ± 7.62⁎
Note: Formula F2–3 consisting of 0.5% SIN was prepared and kept as the gel group, and
0.5% SIN solution was prepared and kept as the control group.
⁎ P b 0.05 vs. control group.
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All the data were processed with SPSS 17.0. All the data were
processed for one-way ANOVA followed by post hoc analysis for signif-
icance with the LSD-t multiple comparison test. P b 0.05 was regarded
as statistically signiﬁcant.
3. Results and discussion
3.1. Selection of vehicle
The use of Carbopol in in situ gelling systems is substantiated by the
property of its aqueous solutions to transform into stiff gels when the
pH is raised [37]. However, the concentration of Carbopol required to
form stiff gels results in highly acidic solutions that are not easily neu-
tralized by the buffering action of the tear ﬂuid. A reduction in Carbopol
concentration without compromising the gelling capacity and rheolog-
ical properties of the delivery system may be achieved by the addition
of viscosity-enhancing polymers such as HPMC. In order to identify
the compositions suitable for use as in situ gelling systems, various con-
centrations of Carbopol andHPMCwere prepared and evaluated for gel-
ling capacity. Table 1 shows that grade “++” of gelling capacity was
more satisfactory. And 0.1% Carbopol/0.4% HPMC was selected as the
developed vehicle for further studies.
3.2. Preparation of formulations
The two main prerequisites of an in situ gelling system are viscosity
and gelling capacity. The formulation should have an optimumviscosityFig. 6. Severity of EAU was scored on a scale of 0 (no disease) to 4 (maximum disease). Dis
(B) 1 = slight iris-vessel dilatation and some anterior chamber cells; (C) 2 = iris hyperemia, w
miotic, irregular, hyperaemic, and (sometimes) slightly damaged iris, with a considerable ﬂare
hyperaemic iris, a miotic pupil often ﬁlled with protein, and cloudy gellike aqueous humor.that will allow easy instillation into the eye as a liquid (drops), which
would undergo a rapid sol-to-gel transition (triggered by a rise in pH
from 5.5 to 7.0). Additionally, to facilitate sustained release of drug to
the ocular tissue, the gel should preserve its integritywithout dissolving
or eroding for a prolonged period of time. SIN-containing F2–3 (0.1%
Carbopol/0.4% HPMC) was selected as the developed formulation,
which has satisfactory attributes of viscosity, gelling capacity and easy
instillation into the eye.3.3. In vitro drug release studies
The release mechanism in vitro was dependent on two simulta-
neous processes: water migration into the in situ gelling system
and drug diffusion. The prolonged release may be probably due to
the formation of hydrogen bonds between drug and polymers,
which have helped in rate control release of drug. In vitro drug re-
lease studies of optimized formulae F2–3 was shown in Fig. 2 by plot-
ting cumulative % drug release vs. time. The results of this study
revealed that, SIN-containing F2–3 released its drug contents, 96.3%,
over a period of 480 min.3.4. Ocular irritation studies
No evidence of overt toxicity was observed in any study, by oph-
thalmoscopic (Fig. 3A) or histopathological evaluation (Fig. 3B), as
indicated by a lack of corneal degeneration, necrosis, inﬂammation,
or edema. Corneas exposed to 0.1% SDS had epithelial (EP) structural
damage due to superﬁcial epithelial cell detachment. Neither the
structure nor the integrity of the corneas was visibly in control
group and gel group. Irritation scores for each formulation group
were less than 2.5, indicating that all formulations were well tolerat-
ed (Table 2). Taking into consideration that the rabbit eye is more
susceptible to irritant substances than the human eye [38], this re-
sult would be considered very promising. Ocular damaging/irritant
agents are currently identiﬁed and evaluated by the Draize rabbit
test, which, however, is being criticized on the basis of ethical con-
siderations and unreliable prognosis of human response [39]. Fur-
ther more studies should be carried out, particularly long-term
administration with penetration enhancers should be concerned.ease severity was clinically assessed with a scale ranging from 0 to 4. (A) 0 = normal;
ith some limitation in pupil dilation, anterior chamber cells, and a slight ﬂare; (D) 3 = a
and cells (especially with accumulation near the iris); (E) 4 = a seriously damaged and
Fig. 7. Clinical scores of the monophasic EAAU (mean ± SD, n = 5). Normal control group
was treated without any drops; blank group was dropped with PBS; control group was
dropped with 0.5% SIN eye drops; gel group was dropped with 0.5% SIN in situ gel; positive
control group was dropped with 1% prednisolone acetate eye drops. dpi = day(s) post im-
munization. Severity of EAAU was scored on a scale of 0 (no disease) to 4 (maximum dis-
ease). Disease severity was clinically assessed with a scale ranging from 0 to 4: 0 =
normal; 1 = slight iris-vessel dilatation and some anterior chamber cells; 2 = Iris hyper-
emia, with some limitation in pupil dilation, anterior chamber cells, and a slight ﬂare; 3 =
a miotic, irregular, hyperaemic, and (sometimes) slightly damaged iris, with a considerable
ﬂare and cells (especially with accumulation near the iris); and 4 = a seriously damaged
and hyperaemic iris, a miotic pupil often ﬁlled with protein, and cloudy gellike aqueous
humor. Data were expressed as mean ± SD. *P b 0.05 vs. gel group, ★P b 0.05 vs. blank
group, one-way ANOVA and followed by Tukey's HSD post-hoc test.
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The results of precorneal retention study of control group and gel
group are shown in Fig. 4.When the preparationwas a gel the ﬂuoresceinFig. 8.Histologic changes in the iris (I), the ciliary body (CB) and the anterior chamber (AC) of bl
the harvested eyes at day 14 post-immunization demonstrated heavy inﬁltration of the inﬂamm
and the anterior chamber (AC) of blank group. In contrast, only few inﬂammatory cells within t
anterior chamber of normal control group showed no inﬁltration with mononuclear cells. Objestayed within the gel and gradually disappeared as the gel was
disintegrating. For the control group, the behavior of the ﬂuorescein
was drastically different, a continuous ﬂow of ﬂuorescein towards
the inner canthus along the eyelid margin was observed. This elimi-
nation of control group and gel group was completed within 10 min
(Fig. 4A) and 25 min (Fig. 4B) in the rabbit eyes, respectively.
In order to increase the effectiveness of the drug a dosage form
should be chosen which increases the contact time of the drug in
the eye. This may then increase the bioavailability, reduce systemic
absorption and reduce the need for frequent administration leading
to improved patient compliance. When a drug solution is dropped
into the eye, the effective tear drainage and blinking action of the
eye result in a 10-fold reduction in the drug concentration within
4–20 min. In this study, the percorneal retention was improved
from 10 min to 25 min, then improved local bioavailability, reduced
dose concentrations and dosing frequency, and improved patient ac-
ceptability, may be achieved.3.6. Pharmacokinetic proﬁles
Microdialysis is a technique used to monitor in vivo the concentra-
tion time course of drugs and endogenous substances in tissue's extra-
cellular ﬂuid [40]. Ocular microdialysis has gained popularity in recent
years due to its ability to continuously monitor drug concentrations
and substantially reduce the number of animals needed [41–43].
Relative recoveries for SIN estimated in in vivo experimentswere ap-
proximately (20.48 ± 2.02) % (n = 3) measured by retrodialysis.
Time–concentration proﬁles of gel group and control group were
shown in Fig. 5 and Table 3. SIN seemed to be eliminated from aqueous
humor according to ﬁrst-order kinetics. Concentrations of SIN in aque-
ous humor increased rapidly after instillation and reached maximal
levels at 40 min in control group. Compared to control group, SIN in
gel group exhibited a 2.70-fold greater AUC0–t and 1.79-fold greater
Cmax than that of control group, while Tmax unchanged.ank group (A), gel group (B) and normal control group (C). Histopathologic examination of
atory cells, mainlymonocytes and T lymphocytes, within the iris (I), the ciliary body (CB)
he iris/ciliary body and the anterior chamber of gel group. And the iris/ciliary body and the
ctive magniﬁcation 20×.
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Disease severity was observed daily by slit-lamp microscopy and
graded as described in the Materials and methods section (Fig. 6A–E).
Based on the clinical course, monophasic EAAU was divided into three
stages: an initiation phase from the day of immunization to 8 day post
immunization, an effector phase beginning from 8 to 15 day post im-
munization, with the peak inﬂammation obtained at 11 day post im-
munization, and a phase of resolution starting from 15 day post
immunization.
The eyes in each group were observed everyday after immuniza-
tion until day 17 post immunization, and clinical scores were
recorded (Fig. 7). The results indicated that gel group and positive
control group developed EAAU later and with lighter inﬂammation
than in blank group and control group. The clinical signs of blank
group such as dilated or engorged blood vessels in iris were observed
on days 8–9 post immunization. The most severe intraocular inﬂam-
mation was detected on days 13–14 post immunization, as
evidenced by an opaque anterior chamber and obscured pupil. On
day 15 post immunization, the ocular inﬂammation was greatly re-
solved, with only minor clinical signs, and no inﬂammatory signs
were detected on day 17 post immunization. Compared with blank
group, there were no inﬂammatory response on day 9 post immuni-
zation and only mild hyperemia of the iris, no hypopyon, normal
pupil were observed on day 11 post immunization in the gel group.
On day 13 post immunization, the ocular inﬂammation was almost
resolved, with only minor clinical signs. No inﬂammatory signs
were detected on day 15 post immunization. Histopathologic exam-
ination of the harvested eyes at day 14 post-immunization demon-
strated heavy inﬁltration of the inﬂammatory cells, mainly
monocytes and T lymphocytes, within the iris (I), the ciliary body
(CB) and the anterior chamber (AC) of blank group (Fig. 8A). In con-
trast, only few inﬂammatory cells were within the iris/ciliary body
and the anterior chamber of the gel group (Fig. 8B). And the iris/cil-
iary body and the anterior chamber of normal control group showed
no inﬁltration with mononuclear cells (Fig. 8C).
In summary, SIN was successfully formulated in pH-triggered in situ
gelling systemusing Carbopol 940 in combinationwithHPMCK4M. The
formulation caused no irritation to rabbit eye tissues. Both the in vitro
and the in vivo results indicated that the in situ gel system is a viable al-
ternative to conventional eye drops by virtue of its ability to enhance
bioavailability through its longer elimination time and the ability to sus-
tain drug release. More importantly, it was a suitable medium for SIN to
treat autoimmune uveitis based on its anti-inﬂammatory and immuno-
regulatory characteristics. Additionally, our results demonstrated that
the topical administration of SIN in situ gel to Lewis rats before the
onset of EAAU inhibited disease assessed both clinically and histologi-
cally. To our knowledge, this study is the ﬁrst to demonstrate that SIN
can be used to inhibit autoimmune uveitis.Acknowledgments
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